OPPORTUNITY! We are looking for Partners to introduce our brand new and innovative line of products in ORAL REHIDRATATION. 1 Reply

Rehidrata is a line of product for oral hydration. Available for hospitals and pharmacies formats. Perfect treatment for patients with Dysphagia. Rehidrata isa brand new product with no competence.For more info please contact me:…Continue

Started by David Lecha in Pharmaceutical Distribution & Licensing Opportunities. Last reply by Neha shamita May 16.

REGENERON - Diversified Pipeline can Buffer the Setback

Despite the setback in the pipeline – negative recommendation from FDA advisory committee on approval of ARCALYST (R, for prevention of gout flares, PDUFA: July 30, 2012), EYLEA (VEGF Trap-Eye, L in US, partnered with Bayer for Ex-US, wet AMD)…Continue

Tags: ARCALYST, anti-VEGF, reimbursement, DME, rilonacept

Started by Jagdish Gohil in Business Development Opportunities May 15.

CIPLA - Nothing New – As Expected

Cipla’s Q4 FY12 result was below our estimate largely because of lower than estimated sales from Lexapro formulations. EBITDA margin remained flat despite increase in sales from Indore facility and ‘some’ sales from generic Lexapro formulations.…Continue

Tags: Akorn, Meda, HFA, Inhalers, Vancocin

Started by Jagdish Gohil in Business Development Opportunities May 15.

CADILA HEALTHCARE - Nearing Inflection Point

Cadila’s Q4 FY12 result was much higher than our estimates owing to better performance across the board on sales and margin. Y-o-Y sales grew by 15.3%, EBITDA grew by 20% and net profit declined by 4.5% due to forex loss. FY12 remained a year of…Continue

Tags: JV, Bayer, Microbix, Astelin, Novavax

Started by Jagdish Gohil in Business Development Opportunities May 15.

GILEAD - After HIV -Poised to Deliver the Best Anti-Viral Treatment Options for HCV!

Gilead’s supremacy in the HIV space in 2012-18 should remain intact with the successful launch of Complera/Eviplera and Quad Pill. At EASL ‘12, impressive data from ELECTRON and QUANTUM study of GS-7977+RBV (PhII, HCV) promises of a possibility of…Continue

Tags: of, drugs, landscape, competitive, treatment

Started by Jagdish Gohil in Pharmaceutical Distribution & Licensing Opportunities May 5.

INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability

Incyte (INCY) reported net revenues of $19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for Ex-US rights) in the 1Q12. We expect strong but gradual…Continue

Tags: intermediate, or, Thrombocythemia, Essential, Vera

Started by Jagdish Gohil in Pharmaceutical Distribution & Licensing Opportunities May 5.